Shots:
Zonsen PepLib Biotech has entered into a worldwide license agreement with Novartis for an undisclosed peptide-based radioligand therapy asset
As per the deal, Novartis will obtain exclusive worldwide rights & lead the development & commercialization activities for the undisclosed asset
In return, PepLib will receive $50M upfront, with additional development, regulatory, & sales milestone payments,…
